All AbMole products are for research use only, cannot be used for human consumption.
For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.
Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and Drug Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection.
| CAS Number | 2135632-29-8 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
[3] No authors listed. Inmazeb
[4] Anthony Markham. Drugs. REGN-EB3: First Approval
[5] No authors listed. Am J Health Syst Pharm. Atoltivimab, Maftivimab, and Odesivimab-ebgn
| Related Anti-infection Products |
|---|
| BTZ043 Racemate
BTZ043 Racemate (BTZ038, BTZ044) is a decaprenylphosphoryl-b-D-ribose 2-epimerase inhibitor. |
| Enoxacin
Enoxacin is a small molecule inhibitor of binding between the B2-subunit of vacuolar H+-ATPase (V-ATPase) and microfilaments. |
| Posaconazole
Posaconazole is a sterol C14α demethylase inhibitor with IC50 of 0.25 nM. |
| Pretomanid
Pretomanid (PA-824) is a novel, orally active nitroimidazole derivative with antimycobacterial activity for use in tuberculosis-related studies. |
| Clofazimine
Clofazimine is a rhimophenazine dye, originally developed for the treatment of tuberculosis, it has both antimicrobial and antiinflammatory activity, postulated mechanisms of action include intercalation of clofazimine with bacterial DNA and increasing levels of cellular phospholipase A2. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
